Immunotech Biopharm Ltd

6978

KYG4721A1004

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
3.45 ^HKD	-1.99%		+2.07%	-31.00%

Mar. 29	Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	MT
Mar. 28	Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Immunotech Biopharm Ltd

Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	Mar. 29	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug	Feb. 19	MT
Immunotech Biopharm Receives an Approval of the Investigational New Drug Application for Phase I Clinical Trial from the Centre for Drug Evaluation of the National Medical Products Administration for the aT19 Injection	Feb. 19	CI
Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection	Jan. 03	CI
Chinese Drug Regulator Accepts Immunotech Biopharm's Application for AT19 Injection	Nov. 27	MT
Immunotech Biopharm Enrolls First Patient in Clinical Trial of Lymphoma Drug	Nov. 07	MT
Immunotech Biopharm Ltd Completes the First Patient Enrolment for its Phase I Clinical Trial for the Denocabtagene Ciloleucel Injection	Nov. 07	CI
China Grants Breakthrough Therapy Designation to Immunotech's Liver Cancer Medication; Shares Fall 5%	23-09-06	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Immunotech Biopharm Ltd Announces Board Changes	23-08-27	CI
Immunotech Biopharm Ltd Announces Director Changes	23-03-26	CI
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Immunotech Biopharm Obtains China Clinical Trial Approval for Lymphoma Treatment	23-03-22	MT
Immunotech Biopharm Ltd Obtains the Clinical Approval for the Denocabtagene Ciloleucel Injection from the National Medical Products Administration	23-03-21	CI
Immunotech Biopharm Extends Completion Date of Convertible Bond Sale	23-01-26	MT
Immunotech Biopharm’s New Drug Application for Lymphoma Injection Accepted by Chinese Regulator	22-12-29	MT
Immunotech Biopharm Ltd. Receives Acceptance Notice for the Investigational New Drug Application for the Denocabtagene Ciloleucel Injection	22-12-28	CI
Immunotech Biopharm Shareholders to Meet on Convertible Bond Issuance	22-12-16	MT
Immunotech Biopharm Ltd announced that it expects to receive CNY 300 million in funding from Tianjin Tasly Pharmaceutical Co., Ltd., Investment Arm	22-10-27	CI
Immunotech Biopharm Sees $19.6 Million H1 Loss	22-09-26	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-26	CI
Immunotech Biopharm, NKY Medical Form Tumor Diagnostics JV in Shanghai	22-06-02	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-25	CI
Immunotech Biopharm Seeks Clinical Trial Nod in China for B-Cell Lymphoma Treatment	22-02-03	MT

Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.

Sector

Biotechnology & Medical Research

Calendar

2024-08-19 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNOTECH BIOPHARM LTD	-31.00%	227M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.37B
ARGENX SE	-1.80%	21.37B
BIONTECH SE	-17.75%	20.92B
GENMAB A/S	-6.91%	18.64B
WUXI APPTEC CO., LTD.	-42.00%	16.4B
BEIGENE, LTD.	-28.19%	13.53B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.28B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.85B